Yi Lin

No bio available.

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Juno/BMS
    Topic: 
    Consulting
    Date added: 
    07/20/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    BlueBird Bio
    Topic: 
    Consulting
    Date added: 
    07/20/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Janssen
    Topic: 
    Consulting
    Date added: 
    07/20/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Legend BioTech
    Topic: 
    Consulting
    Date added: 
    07/20/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Gamida Cells
    Topic: 
    Consulting
    Date added: 
    07/20/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Novartis
    Topic: 
    Consulting
    Date added: 
    07/20/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Iovance
    Topic: 
    Consulting
    Date added: 
    07/20/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Takeda
    Topic: 
    Consulting
    Date added: 
    07/20/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Fosun Kite
    Topic: 
    Consulting
    Date added: 
    07/20/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Pfizer
    Topic: 
    Consulting, Data Review Committee, DSMC
    Date added: 
    07/20/2023

Pages

Return to Seattle Cellular Therapy Summit: Patient-Centered Approach to Improve Outcomes